How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed

David L. Rimm, MD, PhD; Roy Herbst, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer meetings, with adoption of the test predicated on standardization and the perceived value of the test.

September 7, 2018

Working Together to Find the New Standard of Care

Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients.

January 13, 2015

BCI Payer Education

Dr Stephen C. Malamud and Dr Susan K. Boolbol discuss payer adoption of the Breast Cancer IndexSM (BCI) to ensure patient access and cost reimbursement.